MET and neoplasm: Supporting this notion, MET-amplified cell subpopulations have been identified at low frequencies (reportedly representing <1% of tumor cells) in pre-treatment specimens from cases that subsequently exhibited MET-amplification as main mechanism of resistance at disease progression, thus indicating that dominant clones had emerged from the preexisting cells under TKI-induced selective pressure [55,139].